Tag: Big Pharma

AI and big data will continue to disrupt pharmaceutical sector

AI and big data have been identified by healthcare industry professionals as the top technologies that will transform pharmaceutical drug discovery and development processes.

Catalent Plans Multi-Phase, $100 Million Expansion of Italian Facility

Catalent’s Anagni site is a world-class biologics and oral dose manufacturing facility that specializes in late-stage and commercial product launches.

AGC Biologics Eyeing to Significantly Expand Their Cell and Gene Therapy Capabilities

AGC Biologics announced the signing of a purchase agreement for a state-of-the-art Cell and Gene Therapy commercial manufacturing facility in Longmont, currently owned by Novartis Gene Therapies.

Johnson & Johnson agrees to pay $263m to settle NY opioid claims, exits market

Johnson & Johnson has shaken off another lingering liability claim in the US, agreeing a $263 million settlement with...

Servier and PRISM BioLab enter drug discovery collaboration for a novel target

Servier, a global independent pharmaceutical Group, and PRISM BioLab, a Japan based biotechnology company with proprietary small molecule drug...

Eisai and BMS Enter Into Strategic Collaboration for MORAb-202 Antibody Drug Conjugate

Bristol Myers Squibb will pay $650 million U.S. dollars to Eisai including $200 million U.S. dollars as payment toward Eisai research and development expenses.

FDA Approves Pfizer’s Pneumococcal 20-valent Conjugate Vaccine For Adults

The U.S. Food and Drug Administration has approved Pfizer Inc.'s (PFE) PREVNAR 20 or Pneumococcal 20-valent Conjugate Vaccine for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae or pneumococcus serotypes in the vaccine in adults ages 18 years and older.

Six-in-One Pediatric Combination Vaccine Now Available in the United States

This Combination Vaccine May Simplify Execution and Reduce Shots Needed to Complete CDC’s Recommended Child and Adolescent Immunization Schedule VAXELIS™...

Sinopharm’s Wuhan affiliate boosts COVID-19 shot annual capacity to 1 billion doses

A Wuhan-based affiliate of China National Pharmaceutical Group (Sinopharm) said the start of operations at a new factory will raise the annual production capacity of its COVID-19 vaccine to at least 1 billion doses.

Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate

Sanofi and GSK started enrollment in their Phase 3 clinical study to assess the safety, efficacy, and immunogenicity of...